Model N announced that it now manages $1.3 trillion in gross revenue for pharmaceutical and medical technology customers, underscoring the company’s expanding role in helping life sciences manufacturers navigate increasingly complex pricing, revenue, and compliance environments.
The milestone reflects rising demand for integrated solutions as manufacturers face growing gross-to-net complexity driven by regulatory changes, including Medicare price negotiations, 340B compliance requirements, and potential future pricing models such as most-favored-nation frameworks.
Model N’s platform is designed to connect pricing, revenue management, and compliance workflows, enabling companies to improve market access, optimize financial performance, and maintain regulatory alignment across global operations.
Industry data further highlights the challenge, with 99 percent of life sciences leaders reporting increased complexity in gross-to-net processes, according to Model N’s State of Revenue Report. The trend is pushing companies toward more data-driven, automated approaches to revenue operations.
The company also reported strong business momentum, including approximately $25 billion in projected customer savings and more than 20x return on investment based on its internal analyses. Model N has added new customers since late 2025, including Altera, Aptiv Global Operations Limited, Bavarian Nordic, and Cytokinetics.
In addition to customer growth, Model N continues to invest in product innovation and partnerships. Recent initiatives include expanded global market access through a partnership with CCX, the launch of Data nSights, an AI-ready data and analytics platform, and the expansion of agentic workflows across pricing and revenue operations.
The company now serves more than 150 organizations across over 120 countries and has expanded its leadership team across product, technology, customer success, and finance to support its next phase of growth.
KEY QUOTES
“This milestone reflects the critical role Model N plays in helping life sciences manufacturers operate with confidence. As gross-to-net complexity and regulatory change accelerate, manufacturers are turning to trusted partners that can connect pricing, revenue, and compliance, so they can make informed decisions and execute at scale.”
Bret Connor, CEO, Model N
“We’re seeing a shift toward operational readiness as a competitive advantage. Companies that can connect pricing decisions to downstream impact are better positioned to adapt, maintain compliance, and execute at scale.”
Bret Connor, CEO, Model N
